Joseph M. Limber Purchases 5,243 Shares of XOMA Co. (NASDAQ:XOMA) Stock

XOMA Co. (NASDAQ:XOMA) Director Joseph M. Limber acquired 5,243 shares of the company’s stock in a transaction that occurred on Monday, April 7th. The shares were bought at an average cost of $25.60 per share, for a total transaction of $134,220.80. Following the transaction, the director now owns 10,000 shares of the company’s stock, valued at $256,000. This represents a 110.22 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

XOMA Price Performance

Shares of NASDAQ XOMA opened at $20.19 on Thursday. The company has a debt-to-equity ratio of 1.28, a quick ratio of 7.52 and a current ratio of 7.52. The company has a market cap of $241.86 million, a PE ratio of -5.80 and a beta of 1.00. The business has a 50-day simple moving average of $22.36 and a two-hundred day simple moving average of $26.30. XOMA Co. has a fifty-two week low of $18.35 and a fifty-two week high of $35.00.

XOMA (NASDAQ:XOMA) last issued its quarterly earnings results on Monday, March 17th. The biotechnology company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.17). The business had revenue of $8.70 million during the quarter, compared to analyst estimates of $8.75 million. XOMA had a negative return on equity of 24.95% and a negative net margin of 151.34%. As a group, equities analysts expect that XOMA Co. will post -1.41 EPS for the current fiscal year.

Institutional Investors Weigh In On XOMA

Several institutional investors have recently added to or reduced their stakes in XOMA. GAMMA Investing LLC boosted its holdings in XOMA by 1,063.8% in the first quarter. GAMMA Investing LLC now owns 1,734 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 1,585 shares in the last quarter. BNP Paribas Financial Markets boosted its holdings in XOMA by 95.0% in the third quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock worth $43,000 after acquiring an additional 795 shares in the last quarter. New York State Common Retirement Fund raised its stake in shares of XOMA by 51.2% in the fourth quarter. New York State Common Retirement Fund now owns 2,362 shares of the biotechnology company’s stock worth $62,000 after purchasing an additional 800 shares during the last quarter. Wells Fargo & Company MN raised its stake in shares of XOMA by 38.0% in the fourth quarter. Wells Fargo & Company MN now owns 4,300 shares of the biotechnology company’s stock worth $113,000 after purchasing an additional 1,183 shares during the last quarter. Finally, Bank of America Corp DE raised its stake in shares of XOMA by 34.7% in the fourth quarter. Bank of America Corp DE now owns 7,796 shares of the biotechnology company’s stock worth $205,000 after purchasing an additional 2,009 shares during the last quarter. Institutional investors and hedge funds own 95.92% of the company’s stock.

Analysts Set New Price Targets

XOMA has been the topic of a number of recent research reports. HC Wainwright reaffirmed a “buy” rating and set a $104.00 price objective on shares of XOMA in a research report on Friday, March 28th. StockNews.com downgraded XOMA from a “hold” rating to a “sell” rating in a research report on Thursday, April 3rd.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.